Therapeutic Potential of T Cell Chimeric Antigen Receptors (CARs) in Cancer Treatment: Counteracting Off-Tumor Toxicities for Safe CAR T Cell Therapy

Annual Review of Pharmacology and Toxicology

Volumn 56, Issue , 2016, Pages 59-83

  Gross, Gideon ^a,b,c   Eshhar, Zelig ^c,d  

^a MIGAL GALILEE TECHNOLOGY CENTER   (Israel)

^b TEL HAI COLLEGE   (Israel)

^c TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

^d WEIZMANN INSTITUTE OF SCIENCE   (Israel)

Author keywords

Adoptive T cell therapy; Cancer immunotherapy; CARs; Chimeric antigen receptors; On off target effects; Tumor antigens

Indexed keywords

B CELL MATURATION ANTIGEN; CARBONATE DEHYDRATASE IX; CARCINOEMBRYONIC ANTIGEN; CASPASE 9; CD19 ANTIGEN; CD20 ANTIGEN; CD22 ANTIGEN; CELL ADHESION MOLECULE; CHIMERIC ANTIGEN RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; EPITHELIAL MEMBRANE ANTIGEN; FOLATE RECEPTOR 1; MESOTHELIN; MONOCLONAL ANTIBODY; MUCIN 1; PROSTATE SPECIFIC MEMBRANE ANTIGEN; PROSTATE STEM CELL ANTIGEN; T LYMPHOCYTE RECEPTOR; TRASTUZUMAB; TUMOR ANTIGEN; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 1; ANTINEOPLASTIC AGENT; HYBRID PROTEIN; LYMPHOCYTE ANTIGEN RECEPTOR;

ACUTE LYMPHOBLASTIC LEUKEMIA; ACUTE MYELOBLASTIC LEUKEMIA; ANTIGEN EXPRESSION; ANTIGEN RECOGNITION; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLOOD GROUP LEWIS SYSTEM; BRAIN TUMOR; CANCER PATIENT; CANCER THERAPY; CELL THERAPY; HEMATOLOGIC MALIGNANCY; HUMAN; MULTIPLE MYELOMA; NONHODGKIN LYMPHOMA; NONHUMAN; OVARY CANCER; PRIORITY JOURNAL; SOLID TUMOR; SUICIDE GENE; T CELL DEPLETION; T LYMPHOCYTE; THERAPY EFFECT; TISSUE DISTRIBUTION; TUMOR XENOGRAFT; ANIMAL; DRUG EFFECTS; IMMUNOLOGY; METABOLISM; NEOPLASMS;

ANIMALS; ANTIGENS, NEOPLASM; ANTINEOPLASTIC AGENTS; HUMANS; NEOPLASMS; RECEPTORS, ANTIGEN, T-CELL; RECOMBINANT FUSION PROTEINS; T-LYMPHOCYTES;

EID: 84954168391     PISSN: 03621642     EISSN: 15454304     Source Type: Book Series    
DOI: 10.1146/annurev-pharmtox-010814-124844     Document Type: Article

References (152)

1. Gill S, June CH. 2015. Going viral: chimeric antigen receptor T-cell therapy for hematological malignancies. Immunol. Rev. 263:68-89
2. Gross G,Waks T, Eshhar Z. 1989. Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity. PNAS 86:10024-28
3. Eshhar Z, Waks T, Gross G, Schindler DG. 1993. Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and theorsubunits of the immunoglobulin and T-cell receptors. PNAS 90:720-24
4. Eshhar Z. 2014. From the mouse cage to human therapy: A personal perspective of the emergence of T-bodies/chimeric antigen receptor T cells. Hum. Gene Ther. 25:773-78
5. Marincola FM, Jaffee EM, Hicklin DJ, Ferrone S. 2000. Escape of human solid tumors from T-cell recognition: molecular mechanisms and functional significance. Adv. Immunol. 74:181-273
6. Garrido F, Algarra I. 2001. MHC antigens and tumor escape from immune surveillance. Adv. Cancer Res. 83:117-58
7. Crespo J, SunH,WellingTH, Tian Z, ZouW. 2013. Tcell anergy, exhaustion, senescence, and stemness in the tumor microenvironment. Curr. Opin. Immunol. 25:214-21
8. Gross G, Gorochov G,Waks T, Eshhar Z. 1989. Generation of effector T cells expressing chimeric T cell receptor with antibody type-specificity. Transplant. Proc. 21:127-30
9. Eshhar Z. 2008. The T-body approach: redirecting T cells with antibody specificity. Handb. Exp. Pharmacol. 181:329-42
10. Sadelain M, BrentjensR,Riviere I. 2009. The promise and potential pitfalls of chimeric antigen receptors. Curr. Opin. Immunol. 21:215-23
11. Barrett DM, Singh N, Porter DL, Grupp SA, June CH. 2014. Chimeric antigen receptor therapy for cancer. Annu. Rev. Med. 65:333-47
12. Cheadle EJ, Gornall H, Baldan V, Hanson V, Hawkins RE, Gilham DE. 2014. CAR T cells: driving the road from the laboratory to the clinic. Immunol. Rev. 257:91-106
13. Friedmann-Morvinski D, Bendavid A, Waks T, Schindler D, Eshhar Z. 2005. Redirected primary T cells harboring a chimeric receptor require costimulation for their antigen-specific activation. Blood 105:3087-93
14. Kochenderfer JN, Wilson WH, Janik JE, Dudley ME, Stetler-Stevenson M, et al. 2010. Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19. Blood 116:4099-102
15. Kochenderfer JN, Dudley ME, Feldman SA, Wilson WH, Spaner DE, et al. 2012. B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. Blood 119:2709-20
16. Kochenderfer JN, Dudley ME, Carpenter RO, Kassim SH, Rose JJ, et al. 2013. Donor-derived CD19-targeted T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation. Blood 122:4129-39
17. Kochenderfer JN,Dudley ME,Kassim SH, Somerville RPT, Carpenter RO, et al. 2015. Chemotherapyrefractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor. J. Clin. Oncol. 33:540-49
18. Porter DL, Levine BL, Kalos M, Bagg A, June CH. 2011. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N. Engl. J. Med. 365:725-33
19. Kalos M, Levine BL, Porter DL, Katz S, Grupp SA, et al. 2011. T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci. Transl. Med. 3:95ra73
20. Grupp SA, Kalos M, Barrett D, Aplenc R, Porter DL, et al. 2013. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N. Engl. J. Med. 368:1509-18
21. Brentjens RJ, Davila ML, Riviere I, Park J, Wang X, et al. 2013. CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci. Transl. Med. 5:177ra38
22. Davila ML, Riviere I, Wang X, Bartido S, Park J, et al. 2014. Efficacy and toxicitymanagement of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci. Transl. Med. 6:224ra25
23. Maude SL, Frey N, Shaw PA, Aplenc R, Barrett DM, et al. 2014. Chimeric antigen receptor T cells for sustained remissions in leukemia. N. Engl. J. Med. 371:1507-17
24. Lee DW, Kochenderfer JN, Stetler-Stevenson M, Cui YK, Delbrook C, et al. 2014. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: A phase 1 dose-escalation trial. Lancet 385:517-28
25. Löwenberg B, ed. 2014. 56th ASH annual meeting: Abstracts and meeting program. Blood. Vol. 124(21). http://www. bloodjournal. org/content/124/21
26. Wikstrand CJ, Hale LP, Batra SK, Hill ML, Humphrey PA, et al. 1995. Monoclonal antibodies against EGFRvIII are tumor specific and react with breast and lung carcinomas and malignant gliomas. Cancer Res. 55:3140-48
27. Kochenderfer JN, Rosenberg SA. 2013. Treating B-cell cancer with T cells expressing anti-CD19 chimeric antigen receptors. Nat. Rev. Clin. Oncol. 10:267-76
28. Till BG, Jensen MC, Wang J, Chen EY, Wood BL, et al. 2008. Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells. Blood 112:2261-71
29. Till BG, Jensen MC, Wang J, Qian X, Gopal AK, et al. 2012. CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: pilot clinical trial results. Blood 119:3940-50
30. Haso W, LeeDW, ShahNN, Stetler-StevensonM, Yuan CM, et al. 2013. Anti-CD22-chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemia. Blood 121:1165-71
31. Long AH, Haso WM, Orentas RJ. 2013. Lessons learned from a highly-active CD22-specific chimeric antigen receptor. Oncoimmunology 2:e23621
32. Carpenter RO, EvbuomwanMO, Pittaluga S, Rose JJ, RaffeldM, et al. 2013. B-cell maturation antigen is a promising target for adoptive T-cell therapy of multiple myeloma. Clin. Cancer Res. 19:2048-60
33. Vera J, Savoldo B, Vigouroux S, Biagi E, Pule M, et al. 2006. T lymphocytes redirected against the light chain of human immunoglobulin efficiently kill mature B lymphocyte-derived malignant cells. Blood 108:3890-97
34. Ramos CA, Savoldo B, Liu E, Gee AP, Mei Z, et al. 2013. Clinical responses in patients infused with T lymphocytes redirected to target light immunoglobulin chain. Presented at 55th Am. Soc. Hematol. Meet., Dec. 7-10, New Orleans, LA
35. Mannweiler S, Amersdorfer P, Trajanoski S, Terrett JA, King D, Mehes G. 2009. Heterogeneity of prostate-specific membrane antigen (PSMA) expression in prostate carcinoma with distant metastasis. Pathol. Oncol. Res. 15:167-72
36. Parkhurst MR, Yang JC, Langan RC, Dudley ME, Nathan DN, et al. 2011. T cells targeting carcinoembryonic antigen can mediate regression of metastatic colorectal cancer but induce severe transient colitis. Mol. Ther. 19:620-26
37. Wilkie S, Picco G, Foster J, Davies DM, Julien S, et al. 2008. Retargeting of human T cells to tumorassociated MUC1: The evolution of a chimeric antigen receptor. J. Immunol. 180:4901-909
38. Kershaw MH, Westwood JA, Parker LL, Wang G, Eshhar Z, et al. 2006. A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer. Clin. Cancer Res. 12:6106-15
39. Dahan R, Reiter Y. 2012. T-cell-receptor-like antibodies-generation, function and applications. Expert Rev. Mol. Med. 14:e6
40. Willemsen RA, Debets R, Hart E, Hoogenboom HR, Bolhuis RLH, Chames P. 2001. A phage display selected Fab fragment with MHC class I-restricted specificity for MAGE-A1 allows for retargeting of primary human T lymphocytes. Gene Ther. 8:1601-8
41. Willemsen RA, Ronteltap C, Chames P, Debets R, Bolhuis RLH. 2005. T cell retargeting with MHC class I-restricted antibodies: The CD28 costimulatory domain enhances antigen-specific cytotoxicity and cytokine production. J. Immunol. 174:7853-58
42. Stewart-Jones G, Wadle A, Hombach A, Shenderov E, Held G, et al. 2009. Rational development of high-affinity T-cell receptor-like antibodies. PNAS 106:5784-88
43. Zhang G,Wang L, Cui H, Wang X, Zhang G, et al. 2014. Anti-melanoma activity of T cells redirected with a TCR-like chimeric antigen receptor. Sci. Rep. 4:3571
44. Linette GP, Stadtmauer EA, Maus MV, Rapoport AP, Levine BL, et al. 2013. Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma. Blood 122:863-71
45. Cameron BJ, Gerry AB, Dukes J, Harper JV, Kannan V, et al. 2013. Identification of a titin-derived HLA-A1-presented peptide as a cross-reactive target for engineered MAGE A3-directed T cells. Sci. Transl. Med. 5:197ra103
46. Zhong S, Malecek K, Johnson LA, Yu Z, Vega-Saenz de Miera E, et al. 2013. T-cell receptor affinity and avidity defines antitumor response and autoimmunity in T-cell immunotherapy. PNAS 110:6973-8
47. Oren R, Hod-Marco M, Haus-Cohen M, Thomas S, Blat D, et al. 2014. Functional comparison of engineered T cells carrying a native TCR versus TCR-like antibody-based chimeric antigen receptors indicates affinity/avidity thresholds. J. Immunol. 193:5733-43
48. Wang QS,Wang Y, LvHY, HanQW, FanH, et al. 2014. Treatment ofCD33-directed chimeric antigen receptor-modified T cells in one patient with relapsed and refractory acute myeloid leukemia. Mol. Ther. 23:184-91
49. RitchieDS, Neeson PJ,KhotA,Peinert S, TaiT, et al. 2013. Persistence and efficacy of second generation CAR T cell against the LeY antigen in acute myeloid leukemia. Mol. Ther. 21:2122-29
50. Lamers CHJ, Sleijfer S, Vulto AG, KruitWH, KliffenM, et al. 2006. Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: first clinical experience. J. Clin. Oncol. 24:e20-22
51. Lamers CHJ, Langeveld SCL, Groot-van Ruijven CM, Debets R, Sleijfer S, Gratama JW. 2007. Genemodified T cells for adoptive immunotherapy of renal cell cancer maintain transgene-specific immune functions in vivo. Cancer Immunol. Immunother. 56:1875-83
52. Lamers CHJ, Sleijfer S, van Steenbergen S, van Elzakker P, van Krimpen B, et al. 2013. Treatment of metastatic renal cell carcinoma with CAIX CAR-engineered T cells: clinical evaluation and management of on-target toxicity. Mol. Ther. 21:904-12
53. Stancovski I, Schindler DG, Waks T, Yarden Y, Sela M, Eshhar Z. 1993. Targeting of T lymphocytes to Neu/HER2-expressing cells using chimeric single chain Fv receptors. J. Immunol. 151:6577-82
54. Pinthus JH, Waks T, Kaufman-Francis K, Schindler DG, Harmelin A, et al. 2003. Immuno-gene therapy of established prostate tumors using chimeric receptor-redirected human lymphocytes. Cancer Res. 63:2470-76
55. Pinthus JH, Waks T, Malina V, Kaufman-Francis K, Harmelin A, et al. 2004. Adoptive immunotherapy of prostate cancer bone lesions using redirected effector lymphocytes. J. Clin. Investig. 114:1774-81
56. Pinthus JH, FridmanE,Dekel B, Goldberg I, Kaufman-Francis K, et al. 2004. ErbB2 is a tumor associated antigen and a suitable therapeutic target in Wilms tumor. J. Urol. 172:1644-48
57. Globerson-Levin A,Waks T, Eshhar Z. 2014. Elimination of progressive mammary cancer by repeated administrations of chimeric antigen receptor-modified T cells. Mol. Ther. 22:1029-38
58. Morgan RA, Yang JC, Kitano M, Dudley ME, Laurencot CM, Rosenberg SA. 2010. Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol. Ther. 18:843-51
59. Pule MA, Savoldo B, Myers GD, Rossig C, Russell HV, et al. 2008. Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma. Nat. Med. 14:1264-70
60. Louis CU, Savoldo B, Dotti G, Pule M, Yvon E, et al. 2011. Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma. Blood 118:6050-56
61. Park JR, DiGiusto DL, Slovak M, Wright C, Naranjo A, et al. 2007. Adoptive transfer of chimeric antigen receptor re-directed cytolytic T lymphocyte clones in patients with neuroblastoma. Mol. Ther. 15:825-33
62. Thomas AM, Santarsiero LM, Lutz ER, Armstrong TD, Chen YC, et al. 2004. Mesothelin-specific CD8+ Tcell responses provide evidence of in vivo cross-priming by antigen-presenting cells in vaccinated pancreatic cancer patients. J. Exp. Med. 200:297-306
63. Ho M, Hassan R, Zhang J, Wang QC, Onda M, et al. 2005. Humoral immune response to mesothelin in mesothelioma and ovarian cancer patients. Clin. Cancer Res. 11:3814-20
64. Beatty GL, Haas AR, Maus MV, Torigian DA, Soulen MC, et al. 2014. Mesothelin-specific chimeric antigen receptor mRNA-engineered T cells induce antitumor activity in solid malignancies. Cancer Immunol. Res. 2:112-20
65. Beard RE, Zheng Z, Lagisetty KH, Burns WR, Tran E, et al. 2014. Multiple chimeric antigen receptors successfully target chondroitin sulfate proteoglycan 4 in several different cancer histologies and cancer stem cells. J. Immunother. Cancer 2:25
66. Kang HJ, Park JS, Kim DW, Lee J, Jeong YJ, et al. 2012. Adverse pulmonary reactions associated with the use of monoclonal antibodies in cancer patients. Respir. Med. 106:443-50
67. Mardiros A, Dos Santos C, McDonald T, Brown CE, Wang X, et al. 2013. T cells expressing CD123-specific chimeric antigen receptors exhibit specific cytolytic effector functions and antitumor effects against human acute myeloid leukemia. Blood 122:3138-48
68. Pizzitola I, Anjos-Afonso F, Rouault-Pierre K, Lassailly F, Tettamanti S, et al. 2014. Chimeric antigen receptors against CD33/CD123 antigens efficiently target primary acute myeloid leukemia cells in vivo. Leukemia 28:1596-605
69. Gill S, Tasian SK, Ruella M, Shestova O, Li Y, et al. 2014. Preclinical targeting of human acute myeloid leukemia and myeloablation using chimeric antigen receptor-modified T cells. Blood 123:2343-54
70. Santos AM, Jung J, Aziz N, Kissil JL, Puré E. 2009. Targeting fibroblast activation protein inhibits tumor stromagenesis and growth in mice. J. Clin. Investig. 119:3613-25
71. Kraman M, Bambrough PJ, Arnold JN, Roberts EW, Magiera L, et al. 2010. Suppression of antitumor immunity by stromal cells expressing fibroblast activation protein-. Science 330:827-30
72. Petrausch U, Schuberth PC, Hagedorn C, Soltermann A, Tomaszek S, et al. 2012. Re-directed T cells for the treatment of fibroblast activation protein (FAP)-positive malignant pleural mesothelioma (FAPME-1). BMC Cancer 12:615
73. Schuberth PC, Hagedorn C, Jensen SM, Gulati P, van den Broek M, et al. 2013. Treatment ofmalignant pleural mesothelioma by fibroblast activation protein-specific re-directed T cells. J. Transl. Med. 11:187
74. Tran E, Chinnasamy D, Yu Z, Morgan RA, Lee CC, et al. 2013. Immune targeting of fibroblast activation protein triggers recognition of multipotent bone marrow stromal cells and cachexia. J. Exp. Med. 210:1125-35
75. Wang LS, Lo A, Scholler J, Sun J, Majumdar RS, et al. 2014. Targeting fibroblast activation protein in tumor stroma with chimeric antigen receptor T cells can inhibit tumor growth and augment host immunity without severe toxicity. Cancer Immunol. Res. 2:154-66
76. Kakarla S, Chow KKH, Mata M, Shaffer DR, Song XT, et al. 2013. Antitumor effects of chimeric receptor engineered human T cells directed to tumor stroma. Mol. Ther. 21:1611-20
77. Eades-Perner AM, van der Putten H, Hirth A, Thompson J, Neumaier M, et al. 1994. Mice transgenic for the human carcinoembryonic antigen gene maintain its spatiotemporal expression pattern. Cancer Res. 54:4169-76
78. Chmielewski M, Hahn O, Rappl G, Nowak M, Schmidt-Wolf I, et al. 2012. T cells that target carcinoembryonic antigen eradicate orthotopic pancreatic carcinomas without inducing autoimmune colitis in mice. Gastroenterology 143:1095-107. e2
79. ChmielewskiM, Rappl G, Hombach AA, AbkenH. 2013. T cells redirected by a CD3 chimeric antigen receptor can establish self-antigen-specific tumour protection in the long term. Gene Ther. 20:177-86
80. Chan CHF, Stanners CP. 2004. Novel mouse model for carcinoembryonic antigen-based therapy. Mol. Ther. 9:775-85
81. Blat D, Zigmond E, Alteber Z, Waks T, Eshhar Z. 2014. Suppression of murine colitis and its associated cancer by carcinoembryonic antigen-specific regulatory T cells. Mol. Ther. 22:1018-28
82. PiechockiMP, Ho YS, Pilon S,Wei WZ. 2003. Human ErbB-2 (her-2) transgenicmice: A model system for testing her-2 based vaccines. J. Immunol. 171:5787-94
83. Wang LXJ, Westwood JA, Moeller M, Duong CPM, Wei W, et al. 2010. Tumor ablation by genemodified T cells in the absence of autoimmunity. Cancer Res. 70:9591-98
84. John LB,Devaud C, DuongCPM, YongCS, Beavis PA, et al. 2013. Anti-PD-1 antibody therapy potently enhances the eradication of established tumors by gene-modified T cells. Clin. Cancer Res. 19:5636-46
85. Finkle D, Quan ZR, Asghari V, Kloss J, Ghaboosi N, et al. 2004. HER2-targeted therapy reduces incidence and progression of midlifemammary tumors in female murinemammarytumor virushuHER2-transgenic mice. Clin. Cancer Res. 10:2499-511
86. Fedorov VD, Themeli M, Sadelain M. 2013. PD-1-and CTLA-4-based inhibitory chimeric antigen receptors (iCARs) divert off-target immunotherapy responses. Sci. Transl. Med. 5:215ra172
87. Wilkie S, van Schalkwyk MCI, Hobbs S, Davies DM, van der Stegen SJC, et al. 2012. Dual targeting of ErbB2 and MUC1 in breast cancer using chimeric antigen receptors engineered to provide complementary signaling. J. Clin. Immunol. 32:1059-70
88. Kloss CC, Condomines M, Cartellieri M, Bachmann M, Sadelain M. 2013. Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T cells. Nat. Biotechnol. 31:71-75
89. Lanitis E, Poussin M, Klattenhoff AW, Song D, Sandaltzopoulos R, et al. 2013. Chimeric antigen receptor T cells with dissociated signaling domains exhibit focused anti-tumor activity with reduced potential for toxicity. Cancer. Immunol. Res. 1:43-53
90. Kahlon KS, Brown C, Cooper LJN, Raubitschek A, Forman SJ, Jensen MC. 2004. Specific recognition and killing of glioblastoma multiforme by interleukin 13-zetakine redirected cytolytic T cells. Cancer Res. 64:9160-66
91. Kong S, Sengupta S, Tyler B, Bais AJ, Ma Q, et al. 2012. Suppression of human glioma xenografts with second-generation IL13R-specific chimeric antigen receptor-modified T cells. Clin. Cancer Res. 18:5949-60
92. Krebs S, Chow KKH, Yi Z, Rodriguez-Cruz T, Hegde M, et al. 2014. T cells redirected to interleukin-13R 2 with interleukin-13 mutein-chimeric antigen receptors have anti-glioma activity but also recognize interleukin-13R 1. Cytotherapy 16:1121-31
93. Beatty GL, Haas AR, Maus MV, Torigian DA, Soulen MC, et al. 2014. Mesothelin-specific chimeric antigen receptor mRNA-engineered T cells induce anti-tumor activity in solid malignancies. Cancer. Immunol. Res. 2:112-20
94. Wang W, Ma Y, Li J, Shi HS, Wang LQ, et al. 2013. Specificity redirection by CAR with human VEGFR-1 affinity endows T lymphocytes with tumor-killing ability and anti-angiogenic potency. Gene Ther. 20:970-78
95. Marcus A, Waks T, Eshhar Z. 2011. Redirected tumor-specific allogeneic T cells for universal treatment of cancer. Blood 118:975-83
96. Parente-Pereira A, Burnet J, Ellison D, Foster J, Davies DM, et al. 2011. Trafficking of CAR-engineered human T cells following regional or systemic adoptive transfer in SCID beige mice. J. Clin. Immunol. 31:710-18
97. Maliar A, Servais C, Waks T, ChmielewskiM,LavyR, et al. 2012. RedirectedTcells that target pancreatic adenocarcinoma antigens eliminate tumors and metastases in mice. Gastroenterology 143:1375-84. e5
98. Choi BD, Suryadevara CM, Gedeon PC, Herndon JE II, Sanchez-Perez L, et al. 2014. Intracerebral delivery of a third generation EGFRvIII-specific chimeric antigen receptor is efficacious against human glioma. J. Clin. Neurosci. 21:189-90
99. van Schalkwyk MCI, Papa SE, Jeannon JP, Urbano TG, Spicer JF, Maher J. 2013. Design of a Phase I clinical trial to evaluate intratumoral delivery of ErbB-targeted chimeric antigen receptor T-cells in locally advanced or recurrent head and neck cancer. Hum. Gene Ther. Clin. Dev. 24:134-42
100. Adusumilli PS, Cherkassky L, Villena-Vargas J, Colovos C, Servais E, et al. 2014. Regional delivery of mesothelin-targeted CAR T cell therapy generates potent and long-lasting CD4-dependent tumor immunity. Sci. Transl. Med. 6:261ra151
101. Bonini C, Ferrari G, Verzeletti S, Servida P, Zappone E, et al. 1997. HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia. Science 276:1719-24
102. Straathof KC, Pule MA, Yotnda P, Dotti G, Vanin EF, et al. 2005. An inducible caspase 9 safety switch for T-cell therapy. Blood 105:4247-54
103. Di Stasi A, Tey SK, Dotti G, Fujita Y, Kennedy-Nasser A, et al. 2011. Inducible apoptosis as a safety switch for adoptive cell therapy. N. Engl. J. Med. 365:1673-83
104. Wang X, ChangWC, Wong CW, Colcher D, Sherman M, et al. 2011. A transgene-encoded cell surface polypeptide for selection, in vivo tracking, and ablation of engineered cells. Blood 118:1255-63
105. Griffioen M, van Egmond EHM, Kester MGD, Willemze R, Falkenburg JHF, Heemskerk MHM. 2009. Retroviral transfer of human CD20 as a suicide gene for adoptive T-cell therapy. Haematologica 94:1316-20
106. Philip B, Kokalaki E, Mekkaoui L, Thomas S, Straathof K, et al. 2014. A highly compact epitope-based marker/suicide gene for easier and safer T-cell therapy. Blood 124:1277-87
107. Kieback E, Charo J, Sommermeyer D, Blankenstein T, Uckert W. 2008. A safeguard eliminates T cell receptor gene-modified autoreactive T cells after adoptive transfer. PNAS 105:623-28
108. Jena B, Maiti S, Huls H, Singh H, Lee DA, et al. 2013. Chimeric antigen receptor (CAR)-specific monoclonal antibody to detect CD19-specific T cells in clinical trials. PLOS ONE 8:e57838
109. Rosenberg SA. 2014. Finding suitable targets is the major obstacle to cancer gene therapy. Cancer Gene Ther. 21:45-47
110. Davila ML, Brentjens R, Wang X, Riviere I, Sadelain M. 2012. How do CARs work Early insights from recent clinical studies targeting CD19. OncoImmunology 1:1577-83
111. Xu XJ, Zhao HZ, Tang YM. 2013. Efficacy and safety of adoptive immunotherapy using anti-CD19 chimeric antigen receptor transduced T-cells: A systematic review of phase I clinical trials. Leuk. Lymphoma 54:255-60
112. Gill S, Porter DL. 2014. CAR-modified anti-CD19 T cells for the treatment of B-cell malignancies: rules of the road. Expert Opin. Biol. Ther. 14:37-49
113. Hudecek M, Schmitt TM, Baskar S, Lupo-Stanghellini M, Nishida T, et al. 2010. The B-cell tumorassociated antigen ROR1 can be targeted with T cells modified to express a ROR1-specific chimeric antigen receptor. Blood 116:4532-41
114. Hudecek M, Lupo-Stanghellini MT, Kosasih PL, Sommermeyer D, Jensen MC, et al. 2013. Receptor affinity and extracellular domain modifications affect tumor recognition by ROR1-specific chimeric antigen receptor T cells. Clin. Cancer Res. 19:3153-64
115. Hombach A, Heuser C, Sircar R, Tillmann T, Diehl V, et al. 1999. Characterization of a chimeric T-cell receptor with specificity for the Hodgkin's lymphoma-associated CD30 antigen. J. Immunother. 22:473-80
116. Hombach A, Muche JM, Gerken M, Gellrich S, Heuser C, et al. 2001. T cells engrafted with a recombinant anti-CD30 receptor target autologous CD30+ cutaneous lymphoma cells. Gene Ther. 8:891-95
117. Savoldo B, Rooney CM, Di Stasi A, Abken H, Hombach A, et al. 2007. Epstein Barr virus-specific cytotoxic T lymphocytes expressing the anti-CD30 artificial chimeric T-cell receptor for immunotherapy of Hodgkin disease. Blood 110:2620-30
118. Di Stasi A, De Angelis B, Rooney CM, Zhang L, Mahendravada A, et al. 2009. T lymphocytes coexpressing CCR4 and a chimeric antigen receptor targeting CD30 have improved homing and antitumor activity in a Hodgkin tumor model. Blood 113:6392-402
119. Dutour A, Marin V, Pizzitola I, Valsesia-Wittmann S, Lee D, et al. 2012. In vitro and in vivo antitumor effect of anti-CD33 chimeric receptor-expressing EBV-CTL against CD 33+ acute myeloid leukemia. Adv. Hematol. 2012:683065
120. Barber A, Zhang T, Megli CJ, Wu J, Meehan KR, Sentman CL. 2008. Chimeric NKG2D receptor-expressing T cells as an immunotherapy for multiple myeloma. Exp. Hematol. 36:1318-28
121. Barber A, Meehan KR, Sentman CL. 2011. Treatment of multiple myeloma with adoptively transferred chimeric NKG2D receptor-expressing T cells. Gene Ther. 18:509-16
122. Sentman CL, Meehan KR. 2014. NKG2D CARs as cell therapy for cancer. Cancer J. 20:156-59
123. Jiang H, Zhang W, Shang P, Zhang H, Fu W, et al. 2014. Transfection of chimeric anti-CD138 gene enhances natural killer cell activation and killing of multiple myeloma cells. Mol. Oncol. 8:297-310
124. Hong H, Stastny M, Brown C, Chang WC, Ostberg JR, et al. 2014. Diverse solid tumors expressing a restricted epitope of L1-CAM can be targeted by chimeric antigen receptor redirected T lymphocytes. J. Immunother. 37:93-104
125. Shen CJ, Yang YX,Han EQ, Cao N, Wang YF, et al. 2013. Chimeric antigen receptor containing ICOS signaling domain mediates specific and efficient antitumor effect of T cells against EGFRvIII expressing glioma. J. Hematol. Oncol. 6:33
126. Sampson JH, Choi BD, Sanchez-Perez L, Suryadevara CM, Snyder DJ, et al. 2014. EGFRvIII mCARmodified T-cell therapy cures mice with established intracerebral glioma and generates host immunity against tumor-antigen loss. Clin. Cancer Res. 20:972-84
127. Miao H, Choi BD, Suryadevara CM, Sanchez-Perez L, Yang S, et al. 2014. EGFRvIII-specific chimeric antigen receptorTcells migrate to and kill tumor deposits infiltrating the brain parenchyma in an invasive xenograft model of glioblastoma. PLOS ONE 9:e94281
128. Chinnasamy D, Yu Z, TheoretMR, Zhao Y, Shrimali R RK, et al. 2010. Gene therapy using genetically modified lymphocytes targeting VEGFR-2 inhibits the growth of vascularized syngenic tumors in mice. J. Clin. Investig. 120:3953-68
129. Chinnasamy D, Yu Z, Kerkar SP, Zhang L, Morgan RA, et al. 2012. Local delivery of interleukin-12 using T cells targeting VEGF receptor-2 eradicates multiple vascularized tumors in mice. Clin. Cancer Res. 18:1672-83
130. Tchou J, DeMichele A, Domchek S, Fox K, Tweed C, et al. 2011. Pilot clinical trial of autologous Met redirected T cells administered intratumorally and intravenously in patients with operable triple negative breast cancer. Rev. Discuss. Protoc. #1110-1127, Natl. Inst. Health Recomb. DNA Advis. Comm. 127thMeet.
131. Gong MC, Latouche JB, Krause A, Heston WDW, Bander NH, Sadelain M. 1999. Cancer patient T cells genetically targeted to prostate-specificmembrane antigen specifically lyse prostate cancer cells and release cytokines in response to prostate-specific membrane antigen. Neoplasia 1:123-27
132. Maher J, Brentjens RJ, Gunset G, Riviere I, Sadelain M. 2002. Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCR/CD28 receptor. Nat. Biotechnol. 20:70-75
133. Ma Q, SafarM, Holmes E,Wang Y, Boynton AL, Junghans RP. 2004. Anti-prostate specific membrane antigen designer T cells for prostate cancer therapy. Prostate 61:12-25
134. Gade TPF, HassenW, Santos E, Gunset G, Saudemont A, et al. 2005. Targeted elimination of prostate cancer by genetically directed human T lymphocytes. Cancer Res. 65:9080-88
135. Ma Q, Gomes EM, Lo AS, Junghans RP. 2014. Advanced generation anti-prostate specific membrane antigen designer T cells for prostate cancer immunotherapy. Prostate 74:286-96
136. Hombach A, Koch D, Sircar R, Heuser C, Diehl V, et al. 1999. A chimeric receptor that selectively targets membrane-bound carcinoembryonic antigen (mCEA) in the presence of soluble CEA. Gene Therapy. 6:300-4
137. Zhou X, Li J,WangZ, Chen Z, Qiu J, et al. 2013. Cellular immunotherapy for carcinoma using genetically modified EGFR-specific T lymphocytes. Neoplasia 15:544-53
138. Mihara K, Yanagihara K, Takigahira M, Imai C, Kitanaka A, et al. 2009. Activated T-cell-mediated immunotherapy with a chimeric receptor against CD38 in B-cell non-Hodgkin lymphoma. J. Immunother. 32:737-43
139. Mihara K, Bhattacharyya J, Kitanaka A, Yanagihara K, Kubo T, et al. 2012. T-cell immunotherapy with a chimeric receptor against CD38 is effective in eliminating myeloma cells. Leukemia 26:365-67
140. Bhattacharyya J, Mihara K, Kitanaka A, Yanagihara K, Kubo T, et al. 2012. T-cell immunotherapy with a chimeric receptor against CD38 is effective in eradicating chemotherapy-resistant B-cell lymphoma cells overexpressing survivin induced by BMI-1. Blood Cancer J. 2:e75
141. Chu J, Deng Y, Benson DM, He S, Hughes T, et al. 2013. CS1-specific chimeric antigen receptor (CAR)-engineered natural killer cells enhance in vitro and in vivo antitumor activity against human multiple myeloma. Leukemia 28:917-27
142. Morgenroth A, Cartellieri M, Schmitz M, Günes S, Weigle B, et al. 2007. Targeting of tumor cells expressing the prostate stem cell antigen (PSCA) using genetically engineered T-cells. Prostate 67:1121-31
143. Katari UL, Keirnan JM,Worth AC,Hodges SE, Leen AM, et al. 2011. Engineered T cells for pancreatic cancer treatment. HPB 13:643-50
144. Casucci M, Nicolis di Robilant B, Falcone L, Camisa B, Norelli M, et al. 2013. CD44v6-targeted T cells mediate potent antitumor effects against acute myeloid leukemia and multiple myeloma. Blood 122:3461-72
145. Dall P, Herrmann I, Durst B, Stoff-Khalili MA, Bauerschmitz G, et al. 2005. In vivo cervical cancer growth inhibition by genetically engineered cytotoxic T cells. Cancer Immunol. Immunother. 54:51-60
146. Huang G, Yu L, Cooper LJN, Hollomon M, Huls H, Kleinerman ES. 2012. Genetically modified T cells targeting interleukin-11 receptor chain kill human osteosarcoma cells and induce the regression of established osteosarcoma lung metastases. Cancer Res. 72:271-81
147. Chow KKH, Naik S, Kakarla S, Brawley VS, Shaffer DR, et al. 2012. T cells redirected to EphA2 for the immunotherapy of glioblastoma. Mol. Ther. 21:629-37
148. BurnsWR, Zhao Y, FrankelTL, Hinrichs CS, Zheng Z, et al. 2010. A highmolecular weight melanomaassociated antigen-specific chimeric antigen receptor redirects lymphocytes to target human melanomas. Cancer Res. 70:3027-33
149. Schmidt P, Kopecky C, Hombach A, Zigrino P, Mauch C, Abken H. 2011. Eradication of melanomas by targeted elimination of a minor subset of tumor cells. PNAS 108:2474-79
150. Duong CP, Westwood JA, Berry LJ, Darcy PK, Kershaw MH. 2011. Enhancing the specificity of T-cell cultures for adoptive immunotherapy of cancer. Immunotherapy 3:33-48
151. Hegde M, Corder A, Chow KKH,Mukherjee M, Ashoori A, et al. 2013. Combinational targeting offsets antigen escape and enhances effector functions of adoptively transferred T cells in glioblastoma. Mol. Ther. 21:2087-101
152. Cartellieri M, Bachmann M, Feldmann A, Bippes C, Stamova S, et al. 2010. Chimeric antigen receptorengineered T cells for immunotherapy of cancer. J. Biomed. Biotechnol. 2010:956304